Susan Beitzell, APRN
Acute Care · Athens, GANPI 1134639347
Payments from drug & device makers
Across 672 payments — averaging $19.58 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- AbbVie$4K
- Salix Pharmaceuticals, A Division Of Bausch Health US, LLC$2K
- Takeda Pharmaceuticals U.S.A., Inc.$929
- Ardelyx, Inc.$656
- Johnson & Johnson$627
- Sanofi$581
- plus $5K from 31 others
What the payments were for
- Food & beverage$13,159100%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| AbbVie | 187 | $3,798 |
| Salix Pharmaceuticals, A Division Of Bausch Health US, LLC | 135 | $2,026 |
| Takeda Pharmaceuticals U.S.A., Inc. | 50 | $929 |
| Ardelyx, Inc. | 29 | $656 |
| Johnson & Johnson | 26 | $627 |
| Sanofi | 25 | $581 |
| Regeneron Healthcare Solutions, Inc. | 20 | $471 |
| Pfizer | 28 | $469 |
| Bristol Myers Squibb | 28 | $444 |
| Madrigal Pharmaceuticals | 15 | $394 |
| Intercept Pharmaceuticals, Inc. | 17 | $377 |
| Lilly USA, LLC | 14 | $284 |
| QOL Medical, LLC | 11 | $281 |
| Ipsen Biopharmaceuticals, Inc | 10 | $190 |
| Phathom Pharmaceuticals, Inc. | 5 | $167 |
| Mallinckrodt Hospital Products Inc. | 7 | $159 |
| Boston Scientific | 2 | $154 |
| Ironwood Pharmaceuticals, Inc | 7 | $126 |
| Organon | 7 | $109 |
| Merck | 6 | $91 |
| Ferring Pharmaceuticals Inc. | 5 | $82 |
| Sandoz | 4 | $82 |
| Gilead | 4 | $80 |
| E.r. Squibb & Sons, L.L.C. | 1 | $79 |
| Celltrion USA Inc. | 3 | $74 |
| Vivus LLC | 3 | $69 |
| Aimmune Therapeutics, Inc. | 4 | $65 |
| Amgen | 2 | $53 |
| Nestle Healthcare Nutrition Inc. | 3 | $52 |
| Evoke Pharma, Inc. | 3 | $41 |
| Novo Nordisk | 2 | $32 |
| Braintree Laboratories, Inc. | 2 | $32 |
| Fresenius Kabi USA, LLC | 2 | $32 |
| Janssen Scientific Affairs, LLC | 2 | $25 |
| Medtronic | 1 | $14 |
| Mauna Kea Technologies, Inc. | 1 | $10 |
| Intra-sana Laboratories | 1 | $3 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$13,159 in reported general payments places this provider in the 95th percentile of 679 acute care providers in Georgia.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| CreonLipase/Protease/Amylase | 75 | $338,702 |
| LinzessLinaclotide | 232 | $181,613 |
| Humira(Cf) PenAdalimumab | 16 | $168,031 |
| XifaxanRifaximin | 29 | $85,646 |
| XeljanzTofacitinib Citrate | 11 | $57,507 |
| IbsrelaTenapanor Hcl | 22 | $56,630 |
| RezdiffraResmetirom | 11 | $43,245 |
| MotegrityPrucalopride Succinate | 36 | $33,939 |
| ErythromycinErythromycin Base | 16 | $20,901 |
| Pantoprazole Sodium | 1,039 | $11,967 |
| VoqueznaVonoprazan Fumarate | 13 | $10,967 |
| Colestipol Hcl | 170 | $10,134 |
| Famotidine | 577 | $9,910 |
| Sod Sulf-Potass Sulf-Mag SulfSodium, Potassium,mag Sulfates | 130 | $8,572 |
| Balsalazide Disodium | 36 | $8,542 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| AbbVieCreon, Linzess | $3,798 | $520,314307 claims |
| Salix Pharmaceuticals, A Division Of Bausch Health US, LLCXifaxan, Trulance | $2,026 | $94,14440 claims |
| PfizerXeljanz | $469 | $57,50711 claims |
| Ardelyx, Inc.Ibsrela | $656 | $56,63022 claims |
| Madrigal PharmaceuticalsRezdiffra | $394 | $43,24511 claims |
| Takeda Pharmaceuticals U.S.A., Inc.Motegrity | $929 | $33,93936 claims |
| Phathom Pharmaceuticals, Inc.Voquezna | $167 | $10,96713 claims |
| SandozLansoprazole | $82 | $2,78022 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 679 acute care providers in Georgia.
Other acute care in Athens
- Darryl TurnerRinggold$21K
- Bryce CowgillCumming$16K
- Stacy CreelSavannah$15K
- Crystal KuhnCumming$12K
- Mark ClarkGainesville$10K
- Sarah WymanAtlanta$10K
- Jeffrey DillerAustell$10K
- Ayeshia PowellAtlanta$10K
- Mitzi WilliamsGainesville$10K
- Sally WatkinsColumbus$8K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.